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1. Introduction 
Gastrointestinal stromal tumor (GIST) express the cell surface transmembrane receptor KIT 
that has tyrosine kinase activity and is the protein product of the KIT proto-oncogene c-kit. 
Activation or gain-infunction mutation in the c-kit gene has been identified in the majority of 
GIST cases.  
The mutation results in the constitutive activation of KIT signaling, which leads to 
uncontrolled cell proliferation and resistance to apoptosis. Somatic mutation in the c-kit gene 
of GIST has been reported to be associated with aggressive progression and poor prognosis. 
The diameter of the tumor and the mitotic index have been reported as useful indices of the 
biological malignancy of GISTs. However, a few cases in the benign group had high 
cellularity, ulcer formation or metastasis/recurrence. Therefore, other indices of the 
biological malignancy of GISTs are thought to be needed. 
Recently, the Ki-67 labeling index, p53 immunoreaction, and bcl-2 overexpression have each 
been reported to be useful in predicting the potential malignancy in GISTs. In this chapter, 
the reliabilities of the Ki-67 labeling index, the expression of c-kit, p53, and bcl-2, and the 
apoptotic count for predicting potential malignancy were assessed.  
2. Patients and methods 
2.1 Patients 
Twelve patients with gastric or small intestine stromal tumors who underwent surgical 
resection at our department; 11 involving the stomach and the other one involving the small 
intestine, were retrospective analyzed. Nine patients were male, and three were female (age 
range, 47-79 years; mean age, 62.8±10.5 years). The series consisted of seven patients with 
GIST in the upper body of the stomach, one in the upper body of the remnant stomach, two 
in the middle body of the stomach, one in the antrum, and one in the jejunum. Four patients 
who either had metastasis at the time of the initial operation or recurrence after operation 
were classified as the metastasis/recurrence group, whereas the other eight patients are 
surviving without postoperative recurrence. 
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2.2 Clinicopathological study 
As prognostic determinants, we examined mean tumor diameter, and the mitotic index (the 
frequency of mitosis in 50 visual fields at a magnification of ×400). We used Amin’s 
classification of malignant (mitotic index >5/50 high power fields (HPF), irrespective of 
tumor diameter), borderline (mitotic index <5/50 HPF and tumor diameter >5 cm), and 
benign (mitotic index <5/50 HPF and tumor diameter <5 cm). 
2.3 Immunohistochemical staining  
After an initial review of all available hematoxylin and eosin (H&E)-stained slides of the 
surgical specimen, we selected paraffin blocks in which the central region of the tumor was 
clearly revealed, from each case, to study. Serial 4-μm-thick sections were recut from each 
block. One section from each block was stained with H&E. Other sections were 
immunostained for c-kit, CD34, vimentin, α-smooth muscle stain (SMA), desmin, S-100, Ki-
67, p53, and bcl-2. Immunostaining was performed using the dextran polymer method for c-
kit, CD34, α-SMA, desmin, and S-100. Anti-human c-kit rabbit polyclonal antibody (DAKO, 
Kyoto, Japan), anti-human CD34 mouse monoclonal antibody (DAKO), anti-human 
vimentin mouse monoclonal antibody (DAKO), anti-human α-SMA mouse monoclonal 
antibody (DAKO), anti-human desmin mouse monoclonal antibody (DAKO), or anti-human 
S-100 rabbit polyclonal antibody (DAKO) was used as the primary antibody. The 
deparaffinized sections were irradiated by microwaves for 15 min (400W; H2800 microwave 
processor, Energy Beam Sciences) at 90℃ and were incubated with 0.03% H2O2 / methanol 
for 30 minutes for blocking endogenous peroxidase activity. After washing in phosphate 
buffered saline (PBS), the sections were incubated with the primary antibody for 30 minutes 
at room temperature. After rewashing, the sections were further incubated with peroxidase- 
labeled dextran conjugated anti-mouse and anti-rabbit immunoglobulin goat polyclonal 
antibody (DAKO) for 30 min at room temperature. After washing again , the sections were 
developed with chromogen 3,3’- diaminobenzidine tetrahydrochloride. 
Immunostaining was performed using the avidin-biotin complex method for Ki-67, p53, and 
bcl-2. Anti-human Ki-67 mouse monoclonal antibody (MM1 Novocastra, Newcastle, UK), 
anti-human p53 mouse monoclonal antibody (Do-7 Novocastra), or anti-human bcl-2 mouse 
monoclonal antibody (Novocastra) was used as the primary antibody. The deparaffinized 
sections were heated in an autoclave at 120℃ for 5 minutes in citric acid buffer (2 mmol/l 
citric acid and 9 mmol/l trisodium citrate dehydrate, pH6.0) and incubated with 0.03% H2O2 
/ methanol for 30 minutes for blocking endogenous peroxidase activity. After washing in 
PBS, nonspecific binding was blocked by incubating the sections with normal animal serum 
for 20 minutes. The sections were incubated with the primary antibody overnight at 4℃. 
After washing, the sections were further incubated with biotinylated second antibody for 30 
minutes at room temperature. The primary antibody was detected using the avidin-biotin 
peroxidase complex (Vector Laboratories, Burlingame, CA) and 3-amino-9-ethylcarbazole as 
the chromogen. These thin sections were also counterstained with hematoxylin and 
mounted. For immunoreactivity of p53 and bcl-2 proteins, tissue sections with >10% 
immunopositive cells in 1000 tumor cells from three arbitrary microscopic fields were 
defined as being positive (+), and those with <10% immunoreactive tumor cells were 
defined as being negative (-). 
The Ki-67 Index was defined as the percentage of tumor cells displaying immunoreactivity 
in 1000 cells in a ×100 magnified field from five arbitrary microscopic fields.  
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2.4 TUNEL staining  
Apoptotic tumor cells were detected by using the terminal deoxynucleotide transferase-
mediated deoxyuridine triphosphate biotin nick-end labeling (TUNEL) method. The Apo 
Tag in situ detection kit (Intergen, Purchase, NY) was used according to the manufacturer’s 
instructions. The apoptotic count was defined as the mean number of TUNEL-positive cells 
in a ×400 magnified field from 10 arbitrary microscopic fields. 
2.5 Statistical analysis 
Student’s t -test and the chi-square test were used to analyze the data for significant 
differences, and differences were considered statistically significant when P < 0.05. 
Continuous variables were presented as the mean ± SD.  
3. Clinicopathological study 
3.1 Clinicopathological features 
In six cases, the lesion was incidentally discovered during a routine screening examination. 
The other six cases were symptomatic and presented epigastric pain, abdominal discomfort, 
anemia, vomiting, an abnormal shadow on chest X-ray, or tumor palpable, respectively. The 
lesion size ranged from 18 to 200 mm in diameter (mean size 55.0±44.5 mm) . The GIST in 
the jejunum was palpable. The macroscopic aspects of GIST in the jejunum are a smooth 
surface, gray color, pseudocapsule, and exophitic growth. We found one case with liver 
metastasis, one with lung metastasis, one with bone metastasis, and no cases with lymph 
node metastasis at the time of surgery (Table 1). 
3.2 Histology and malignancy  
A Mitotic Index of > 5/50 HPF was seen in five cases and <5/50HPF in the other seven 
cases.  A high cellularity was seen in four cases, a middle cellularity in four cases, and a low 
cellularity was seen in the other four cases. Concerning the degree of anaplasia, a high 
degree was seen in three cases, a middle degree in four cases, and a low degree was seen in 
the other five cases. The number of cases with ulcer formation, cases with necrosis, cases 
with bleeding in the tumor, and the number of cases with mucosal invasion by tumor cells 
was four, one, four, and one, respectively. The numbers in the malignant group, borderline 
group, and in the benign group were five, two, and five, respectively. Three of four cases in 
the metastasis/recurrence group were malignant group, but other one was benign group. 
All four cases in the metastasis/recurrence group had ulcer formation and high cellularity. 
One case with necrosis and mucosal invasion had lung metastasis. Two of four cases with 
bleeding in the tumor was in the metastasis/recurrence group. Two of three cases with high 
atypia was in the metastasis/recurrence group. In the malignant group, the tumor size was 
>5 cm in diameter in three cases, the cellularity in four cases was middle or high, three cases 
had ulcer formation, three cases had bleeding in the tumor, and one case had necrosis in the 
tumor with mucosal invasion by tumor cells. In the boderline group, the cellularity was 
middle or low, the degree of anaplasia was high or low, one case had bleeding in the tumor, 
and there was no ulcer formation, no necrosis in the tumor, and no mucosal invasion. In the 
benign group, the tumor size was 3 cm or less in diameter. The cellularity was low in two 
cases, middle in two cases, and high in one case. The degree of anaplasia was low in three 
cases, middle in two cases, and high in no case. One case with bone metastasis had ulcer 
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formation . There was no necrosis, no bleeding in the tumor, and no mucosal invasion 
(Table 1). 
 
 
U: upper body of the stomach, M: middle body of the stomach, L: lower body of the stomach, J: 
jejunum,   *mucosal invasion,  **upper part of the remnant stomach 
Table 1. Histological findings and malignancy 
The diameter of the tumor and the mitotic index have been reported as useful indices of 
biological malignancy in GISTs. We used Amin’s classification, preparing evaluation criteria 
based on the pattern of mitosis and the diameter of the tumor. Mucosal invasion, bleeding, 
necrosis, and high degree of anaplasia were not recognized in the benign group. However, 
one case with bone metastasis in benign group had high cellularity and ulcer formation. 
Therefore, the diameter of the tumor and the mitotic index were not only useful indices of 
biological malignancy, but also cellularity, ulcer formation, necrosis, bleeding in the tumor, 
anaplasia, and mucosal invasion.  
3.3 Treatment 
Concerning the treatment, local resection was performed in eight cases, and in five of 
these cases, laparoscopic local resection was performed. In the other four cases, proximal 
gastrectomy with intrahepatic arterial infusion of adriamycin, resection of the remnant 
stomach with left lower lobectomy of the lung, local resection with radiation for bone 
metastasis and partial resection of the jejunum including the tumor were performed 
(Table 2).  
3.4 Prognosis 
Concerning survival, one patient with lung metastasis received resection of the remnant 
stomach with left lower lobectomy of the lung, and later died of intra-abdominal and right 
lung recurrence at 35 months later. One patient with multiple liver metastasis received 
proximal gastrectomy with intrahepatic arterial infusion of adriamycin,  recurrence in the 
abdomen was recognized, removed and imatinib was administered from 41 months, but 
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died of peritoneal metastasis at 58 months after the first surgery. The prognosis of the 
patient with bone metastasis received local resection with radiation was unknown. The 
patient with the large GIST in the jejunum received partial resection of the jejunum 
including the tumor, recurrence in the liver was recognized and imatinib was administered 
from 25 months, local recurrence was recognized in the small intestine and removed at 45 
months, and was still alive at 75 months after the first surgery (Table 2). The other patients 
are still alive and disease-free.  
 
Case  Age   Sex             Treatment                                  Recurrence        Imatinib      Prognosis 
   1      49       M       Proximal gastrectomy               41M peritoneum          +            58M dead  
                             Intrahepatic arterial infusion* 
   2      68      M       Laparoscopic local resection                    -                        -              8M alive 
   3      63      M       Laparoscopic local resection                    -                        -          120M alive 
   4      55      M       Resection of the                      30M peritoneum,lung       -           35M dead 
                                remnant stomach 
                                Lt. lower lobectomy of the lung 
   5      64      M       Laparoscopic local resection                    -                         -           79M alive 
   6      66      F         Local resection                                           -                         -             8M alive  
   7      70      F         Laparoscopic local resection                    -                         -             8M alive 
   8      47     M        Local resection                                            -                         -         128M alive 
   9      78      F         Local resection, Radiation                        -                         -                 -   - 
 10      51     M        Laparoscopic local resection                     -                         -           49M alive 
 11      63     M        Local resection                                            -                         -           34M alive 
 12      79     M        Partial resection of jejunum             25M Liver,                +          75M alive 
                               Tumor resection                                 45M Local recurrence 
*: Intrahepatic arterial infusion of adriamycin 
Table 2. Treatment and prognosis 
4. Immunohistochemical staining 
4.1 c-kit expression 
All patients were positive for vimentin expression. Seven patients were positive for c-kit 
expression. Nine patients were positive for CD34 expression. In the seven c-kit-positive 
cases, six patients were also positive for CD34 expression. Two patients were positive for α-
SMA expression. All patients were negative for both desmin and S-100 expression. All four 
cases in the metastasis/recurrence group were positive for c-kit expression (Table 3). The 
positive rate of c-kit in the malignant group was 100% (five of five), in the borderline group, 
it was 50% (one of two), and in the benign group, it was 20% (one of five; Table 4)).The 
positive rate of c-kit in the malignant group was significantly higher than in the borderline 
and benign group (P < 0.05). Mean tumor size in the c-kit –positive group was 76.4 ± 62.2 
mm and c-kit-negative group was 33.0 ± 21.0 mm (Table 5).The mean tumor diameter in the 
c-kit-positive group was higher than that in the c-kit-negative group. 
Concerning any correlation between cellularity and c-kit expression, the positive rate of c-kit 
in the high group was 100% (four of four), in the middle group was 50% (two of four), and 
in the low group was 25% (one of four). Concerning any correlation between the degree of 
anaplasia and the c-kit expression, the positive rate of c-kit in the high group was 100% 
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(three of three), in the middle group was 75% (three of four), and in the low group was 20% 
(one of five). The positive rate of c-kit in cases with ulcer formation was 100% (four of four), 
and in cases without ulcer formation it was 37.5% (three of eight). The positive rate of c-kit 
in cases with bleeding in the tumor was 100% (four of four), and in cases without bleeding 
in the tumor, it was 37.5% (three of eight). All malignant cases, cases with high cellularity, 
cases with high degree of anaplasia, cases with ulcer formation, and cases with bleeding in 
the tumor were positive for c-kit expression.  
Immunohistochemistry analyses have been reported to show a positivity reaction to CD34 
in > 80% of cases, and to the c-kit in 95-100%. In our study, the positive rate to CD34 was 
83.3%, and to the c-kit it was 66.7%. Therefore, the positive rate to the c-kit was lower than 
in other reports. However, all other reported cases lacked immunohistochemical evidence of 
smooth muscle or neural differentiation. Hirota reported that some GISTs lacked 
immunoreactivity to c-kit without immunohistochemical evidence of smooth muscle or 
neural differentiation. Many GISTs showed a positivity to CD34 recognized in endothelial 
cells and in interstitial cells of Cajal. The positive rate to α-SMA was 16.7% in our cases. 
Hirota reported that from 20 to 30% of GISTs were positive to α-SMA. Somatic mutation in 
the c-kit gene of GIST has been reported to be associated with aggressive progression and 
poor prognosis. Ernst reported that the 3-year survival rate of cases without mutation in c-
kit was >65%, but that of cases with mutation in c-kit it was < 30%. In our cases, all 
malignant cases were c-kit positive, and in the benign group only one case which had bone 
metastais was c-kit positive. The average diameter in the c-kit-positive group was higher 
than that in the c-kit-negative group.  
The expression of c-kit was considered to reflect the malignancy of the GIST. It has recently 
been clarified that the autoactivation of tyrosin kinase caused by upregulation of the c-kit 
gene was related essentially to proliferation in the GIST cells, and imatinib, which inhibits 
the autoactivation of tyrosine kinase, has been reported to be effective as a molecule-
targeting treatment. Although adjuvant use of imatinib is currently under evaluation, it is 
expected to be a useful treatment for an unresectable GIST or for a patient with 
metastasis/recurrence. 
4.2 The Ki-67 labelling index 
Immunoreactivity to Ki-67 was seen in the nucleus of tumor cells (Fig. 1). The Ki-67 labeling 
index ranged between 4.7 to 49.8 (mean 25.4±15.9; Table 3). In the metastasis/recurrence 
group, the Ki-67 labeling index in patient with liver metastasis was 49.8, in patient with bone 
metastasis was 26.8, in patient with lung metastasis, it was 40.2, and in small intestinal GIST 
patient with recurrence in the liver, it was 34.6. The Ki-67 labeling index in the malignant 
group was 35.3±11.0, in the borderline group 37.5±9.40, and in the benign group was 10.6±9.26 
(Table 4). The Ki-67 labeling index in the malignant group was significantly higher than that in 
the benign group (p < 0.01). The Ki-67 labeling index in the c-kit-positive cases was 35.3±10.2 
and in c-kit- negative cases was 11.4±11.0. The Ki-67 labeling index in the c-kit positive cases 
was significantly higher than that in the c-kit-negative cases (p < 0.01). 
The Ki-67 labeling index in the c-kit-positive cases was 35.3±10.2 and in c-kit- negative cases 
was 11.4±11.0 (Table 5). The Ki-67 labeling index in the c-kit positive cases was significantly 
higher than that in the c-kit-negative cases (p < 0.01). 
AgNOR staining, DNA ploidy pattern of the nucleus, bromodeoxyuridine labeling index, 
Ki-67 labeling index, proliferative cell nuclear antigen (PCNA), and p53 staining have each 
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been reported to be a useful marker as an index of malignancy in GIST. Especially, the Ki-67 
labeling index has recently been used as an excellent index of cell growth. The mitotic index 
reflects the M stage of mitosis only; however, because the Ki-67 labeling index can recognize 
most proliferating cells in stages G1, S, and G2, it is considered to be more appropriate as an 
objective index of the malignancy in GIST. Shimoda et al. reported that the Ki-67 labeling 
index was > 10% in all patients with a mitotic index > 10/200 HPF. Wang et al. reported that 
the prognosis of GIST was significantly poor when the Ki-67 labeling index was 10% or 
more. Nagasako et al reported that the maximum tumor diameter, mitotic index, and Ki-67 
labeling index were useful as indices of malignancy for a gastric stromal tumor. In the 
present study, all four cases of the metastasis/recurrence group showed a high Ki-67 
labeling index (49.8, 26.8, 40.2 and 34.6), and the mean Ki-67 labeling index in the malignant 
group was higher than that in the benign group. Even in the benign group, one case with 
bone metastasis showed a high Ki-67 labeling index (26.8), and this case showed high 
cellularity and had ulcer formation. Such a case should be carefully followed 
postoperatively. The mean Ki-67 labeling index in the c-kit-positive cases was higher than 
that in the c-kit-negative cases. The Ki-67 labeling index was considered to be a useful 
marker of malignancy in GIST.  
 
 
Fig. 1. Immunoreactivity for Ki-67; Immunostaining for Ki-67 was confined to almost the 
entire nucleus (×200) 
4.3 p53 expression 
The immunoreactivity of p53 was also mainly identified in the nucleus (Fig. 2). Four patients 
were positive for p53 expression. Three cases of the metastasis/recurrence group were 
positive for p53 expression. The positive rate of p53 in the malignant group was 60.0% (three 
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of five), in the borderline group was 50.0% (one of two), and in the benign group was 
0%(zero of five; Table 4). The mean tumor size in the p53-positive group was 115.0±61.9 mm 
and in the p53-negative group was 26.3±11.9 mm. The mean tumor size in the p53-positive 
group was higher than that of p53- negative group.  
 
 
Fig. 2. p53 staining; Immunohistochemical staining with a monoclonal antibody against p53. 
Nuclear staining was observed in the tumor cells (×400). 
The mean Ki-67 labeling index in the p53-positive group was 38.9±8.26 and in the p53-
negative group was 18.6±14.6. The mean Ki-67 labeling index in the p53-positive group was 
significantly higher than that in the p53-negative group (p < 0.05).  
The p53- positive rate in the c-kit-positive group was 42.9% (three of seven), and in the c-
kit-negative group was 20.0% (one of five), with no significant difference between them 
(Table 5). 
Following DNA damage, p53 protein levels rise dramatically, and the entry into S is delayed 
until the genomic lesions are fully repaired. When the p53 function is lost, cells enter S 
without appropriate DNA repair, leading to fixation and propagation of genetic alterations. 
p53 overexpression promotes the transcription of p21, the product of which causes growth 
arrest through inhibition in Cdks, which are required for G1 to S transition. p21 is induced 
by DNA-damaging agents that trigger G1 arrest or apoptosis in cells with wild type p53 but 
not in tumor cells harboring a deletion or mutation in the p53 gene. Nikaido et al. reported 
that survival in gastric leiomyosarcoma of p53-positive cases was significantly shorter than 
that of p53- negative cases, that immunohistochemical p53 positivity was correlated with 
malignant behavior, and that p53 immunoreaction was a prognostic variable. In our cases, 
three cases of the metastasis/recurrence group were positive for p53 expression. The Ki-67 
labeling index in all p53 –positive cases was >30%. There was no p53-positive case in the 
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benign group. The mean tumor diameter of the p53-positive cases was higher than that of 
the p53-negative cases. The mean Ki-67 labeling index of the p53-positive cases was higher 
than that of the p53-negative cases. The expression to p53 was considered to be a useful 
marker as an index of malignancy and prognosis in GIST.  
4.4 bcl-2 expression    
The immunoreactivity of bcl-2 was mainly identified in the cytoplasm of tumor cells (Fig. 3). 
Seven patients were positive for bcl-2 expression (Table 3).  
 
 
Fig. 3. bcl-2 staining; Immunohistochemical staining with a monoclonal antibody against 
bcl-2. Positive staining was observed in the cytoplasm of the tumor cells (×400).  
All four cases of the metastasis/recurrence group were positive for bcl-2 expression 
(Table 3). The positive rate of bcl-2 in the malignant group was 60.0% (three of five), in 
the borderline group 50.0% (one of two) and in the benign group it was 60.0% (three of 
five; Table 4). The mean tumor size in the bcl-2-positive group was 77.1±64.4 mm, and 
in the bcl-2- negative group was 32.0±14.4 mm, with no significant difference between 
them.  
The mean Ki-67 labeling index in the bcl-2-positive group was 28.3±15.8 mm, and in the bcl-
2-negative group was 21.3±17.0 mm, with no significant difference between them.  
The bcl-2-positive rate in the c-kit-positive group was 57.1% (four of seven), and in the c-
kit-negative group was 60.0% (three of five), with no significant difference between them 
(Table 5).  
The bcl-2-positive rate in the p53-positive group was 100% (four of four), and in the p53- 
negative group was 37.5% (three of eight), with no significant difference between them. 
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Cunningham et al. reported that the patients whose tumor demonstrated staining for bcl-2 
protein had a shorter survival compared with those whose tumor did not demonstrate bcl-2. 
Noguchi et al. reported that overexpression in bcl-2 may play an important role in 
increasing the malignant potential, and furthermore, that the Ki-67 labeling index and bcl-2 
overexpression may be useful in predicting malignant potential. In our study, all four cases 
of the metastasis/recurrence group were positive for bcl-2 expression, and all p53-positive 
cases were positive for bcl-2 expression. However, no significant correlation was observed 
between the frequency of the bcl-2 overexpression and the malignancy in the GIST, tumor 
diameter, or Ki-67 labeling index, 
5. TUNEL staining 
Positive staining was recognized in the nuclei in the apoptotic tumor cells (Fig. 4). The 
apoptotic count ranged between 0.1 to 3.9 (mean 1.20±1.14; Table3). The apoptotic count in 
the malignant group was 1.44±1.65, in the borderline group was 0.50±0.57, and in the benign 
group was 0.80±0.71, with no significant difference among them. The apoptotic count in the 
c-kit-positive group was 1.44±1.32, and in the c-kit-negative group was 0.88±0.88, with no 
significant difference between them (Table 5). The mean apoptotic count in the p53-positive 
group was 2.33±1.20, and in the p53-negative group  was 0.65±0.62. The mean apoptotic 
count in the p53-positive group was higher than that in the p53-negative group. The mean 
apoptotic count in the bcl-2- positive group was 1.80±1.16, and in the bcl-2-negative group it 
was 0.38±0.36, with a significant difference (p < 0.05). All apoptotic counts of malignant 
group or metastasis/recurrence group were 1.0 or > 1.0.  
 
 
Fig. 4. TUNEL staining; TUNEL-positive staining was recognized in the nucleus of apoptotic 
tumor cells (×200).  
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Case   c-kit   CD34    Vimentin  -SMA Desmin S-100    p53   bcl-2     Ki-67     Apoptosis  
  1          +        +             +              -            -           -          +       +          49.8            2.0 
  2          +        +             +              +           -           -           -        -          19.8            0.1 
  3          +        -              +              +           -           -           -        -          32.1            0.2 
  4          +        +             +              -            -           -          +       +          40.2            1.0 
  5          +        +             +              -            -           -           -        -          44.1            0.9 
  6          -         +             +              -            -           -          +       +          30.8            2.4 
  7          -         +             +              -            -           -           -       +            9.7            0.6 
  8          -         -              +              -            -           -           -        -            4.7            0.6 
  9          +        +             +              -            -           -           -       +          26.8            2.0 
 10         -         -              +              -            -           -           -       +            6.1            0.7  
 11         -         +             +              -            -           -           -        -            5.6            0.1 
 12         +        +             +              -            -           -           +       +         34.6            3.9  
Table 3. Results from immunohistochemistry, Ki-67 index and the apoptotic count 
 
 Malignant                 Borderline                Benign 
            (n=5)                       (n=2)                       (n=5) 
Ki-67 Index* 
 
Apoptotic count 
 
p53 positive cases 
 
bcl-2 positive cases 
 
c-kit positive cases** 
         35.3±11.0               37.5±9.40               10.6±9.26 
 
         1.44±1.65               0.50±0.57               0.80±0.71 
 
          3 (60.0%)                  1 (50.0%)                     0 
 
          3 (60.0%)                  1 (50.0%)               3 (60.0%) 
 
          5 (100%)                   1 (50.0%)               1 (20.0%) 
*: The Ki-67 Index in the malignant group was significantly higher than that in the benign group  
(p < 0.01). 
**: The positive rate of c-kit in the malignant group was significantly higher than in the borderline and 
benign group (P < 0.05). 
Table 4. Ki-67 index, Apoptotic Count and the expressions of p53, bcl-2 and c-kit according 
to Malignancy 
Concerning apoptosis, Cunningham et al. reported that inhibition in apoptosis may be 
associated with malignant behavior in patients with gastrointestinal stromal/smooth muscle 
tumors. Yuki et al. reported that the apoptotic cell counts of leiomyosarcoma were 
significantly higher than those of leiomyoma, but this seems not to be a practical index for 
discrimination because apoptotic cell death is a rare event in gastrointestinal myogenic 
tumors. In our study, there was no significant difference in apoptotic count among the 
benign group, borderline group, and the malignant group. The mean apoptotic count in the 
bcl-2-positive group was higher than that in the bcl-2-negative group, and the mean 
apoptotic count in the p53-positive group was higher than that in the p53-negative group. 
p53 induces upregulation in bax protein which accelerates apoptotic death. bcl-2 protein is 
able to repress a number of apoptotic death programs. bax homodimerizes and forms 
heterodimers with bcl-2 in vivo. The ratio of bcl-2 to bax determines survival or death 
following an apoptotic stimulus. Therefore, if overexpressed bax countered the death 
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repressor activity of bcl-2, and apoptosis was considered to be induced in cases that were 
positive for bcl-2 expression. 
 
          c-kit-positive cases           c-kit-negative cses 
                   (n=7)                             (n=5) 
Tumor size 
 
Ki-67 Index* 
 
Apoptotic count 
 
 p53-positive cases 
 
 bcl-2-positive cases 
               76.4±62.2 mm                 33.0±21.0 mm 
 
                35.3±10.2                        11.4±11.0 
 
                1.44±1.32                         0.88±0.88 
 
                  3 (42.9%)                       1 (20.0%) 
 
                  4 (57.4%)                       3 (60.0%) 
*: Mean Ki-67 Index in the c-kit-positive cases was significantly higher than that in the c-kit-negative 
cases (p < 0.01).  
Table 5. Tumor Size, Ki-67 index, apoptotic count, and the expressions of p53 and bcl-2 
according to the expression of c-kit 
6. Conclusion 
Here, we report the Ki-67 labeling index, the expression of c-kit, p53, bcl-2, and apoptosis in 
eleven gastrointestinal stromal tumors (GISTs). The positive rate of c-kit in the malignant 
group was higher than in the borderline and benign group . The Ki-67 labeling index in the 
malignant GIST group was higher than that in the benign group. The Ki-67 labeling index in 
the c-kit-positive group was higher than that in the c-kit-negative group. The Ki-67 labeling 
index in the p53-positive cases was higher than that in the p53-negative cases. The bcl-2 
expression was not correlated with potential malignancy. All metastasis/recurrence cases 
were bcl-2 positive. The apoptotic count in the bcl-2-positive cases was higher than that in 
the bcl-2-negative cases. All apoptotic counts of malignant group or metastasis/recurrence 
group were 1.0 or > 1.0.  
The high Ki-67 labeling index, the c-kit positive, the p53 over expression, the bcl-2 over 
expression and high apoptotic count were useful in predicting the potential malignancy of 
GIST. 
7. References 
Hirota, S. (1998). Gain-of-function mutation of c-kit in human gastrointestinal stromal 
tumors. Science, 279,577-580 
Nishida T. (2000). Clinicopathological features of gastric stromal tumors. J Exp Clin Cancer, 
19,417-425 
Ernst SI. (1998). KIT mutation portends poor prognosis in gastrointestinal stromal/smooth 
muscle tumors. Lab Invest, 78,1633-1636. 
Miettinen M. (2002). Evaluation of malignancy and prognosis of gastrointestinal stromal 
tumors. Hum Pathol, 33,478-483 
www.intechopen.com
The Significance of the Ki-67 Labeling Index, the Expression of c-kit, p53, and bcl-2,  
and the Apoptotic Count on the Prognosis of Gastrointestinal Stromal Tumor 
 
119 
Wang X. (2002) Gastrointestinal stromal tumors: Are they of Cajal cell origin? Exp Mol Pathol 
,72,172-177 
Hasegawa T. (2002). Gastrointestinal stromal tumors: consistent CD117 immunostaining for 
diagnosis and prognostic classification based on tumor size and MIB-1 grade. Hum 
Pathol, 33,669-676 
Abdulkader I. ((2002). Predictors of malignant behavior in gastrointestinal stromal tumors : 
a clinicopathological study of 34 cases. Eur J Surg, 168,288-296 
Shimoda T. (2002). A concept and issue of GIST (gastrointestinal stromal tumor). Pathol Clin 
Med, 20,134-140 
Wang X. (2002). Helpful parameter for malignant potential of gastrointestinal stromal 
tumors (GIST). Jpn J Clin Oncol, 9,347-351 
Noguchi T. (2002). Biological analysis of gastrointestinal stromal tumors. Oncol Rep, 9, 1277-
1282 
Nagasako Y. (2003). Evaluation of malignancy using Ki-67 labeling index for gastric stromal 
tumor. Gastric Cancer, 6,168-172 
Cunningham RE. (2001). Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal 
stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol, 9,19-23 
Amin MB. (1993). Prognostic value of proliferating cell nuclear antigen index in gastric 
stromal tumors: correlation with mitotic count and clinical outcome. Am J Clin 
Pathol, 100,428-432 
Strickland L. (2001). Gastrointestinal stromal tumors. Cancer Control, 8,252-261 
Fujimoto Y. (2003). Clinicopathologic study of primary malignant gastrointestinal tumor of 
the stomach, with special reference to prognostic factors: analysis of results in 140 
surgically resected patients. Gastric Cancer, 6, 39-48 
Hirota S. (2003). Gain-of-function mutation of c-kit gene and molecular target therapy in   
GISTs. Jpn J Gastroenterol, 100,13-20 
Joensuu H. (2001). Effect of the tyrosin kinase inhibitor ST1571 in a patient with a metastatic 
gastrointestinal tumor. N Engl J Med, 344,1052-1056 
Nikaido T. (1995). An analysis of predicting prognostic factors of the gastric 
leiomyosarcoma – a comparative study of their proliferative activity using mitotic 
index, MIB-1, DNA flow cytometry, and p53 immunostaining. Stomach and Intestine, 
30,1125-1132 
Yuki M. (1995). Cell proliferation and cell death (apoptosis) as indices differentiating 
malignant from benign gastrointestinal myogenic tumors. Jpn J Gastroenterol, 92, 
206-216  
Baak JPA. (1991). Mitosis counting in tumors. Hum Pathol, 21,683-685 
Xiong Y. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366,701-704. 
El-Deiry W. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer 
Res, 54,1169-1174 
Dulic V. (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human 
fibroblasts during radiation-induced G1 arrest. Cell, 76,1013-1023 
Miyashita T. (1995). Tumor suppressor p53 is a direct transcriptional activator of human bax 
gene. Cell, 80, 293-299 
Boise LH. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of 
apoptotic cell death. Cell, 74,597-608 
www.intechopen.com
 
Gastrointestinal Stromal Tumor 
 
120 
Oltvai ZN. (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that 
accelerates programmed cell death. Cell, 27,609-619 
www.intechopen.com
Gastrointestinal Stromal Tumor
Edited by Prof. Raimundas Lunevicius
ISBN 978-953-51-0580-0
Hard cover, 120 pages
Publisher InTech
Published online 27, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Almost 30 years have gone by since the postulation that GISTs derive from mesenchymal stem elements, and
only 15 years have gone by since the definitive detection of origin of GISTs. Research in the last decade was
more focused upon the justification of imatinib mezylate therapy in GISTs and clarification why a secondary
resistance that occurred during the kinase inhibitors therapy. The era of therapy for GISTs, targeting the
primary activating mutations in the KIT proto-oncogene; is being proclaimed as bringing the message of
special importance to the pathologist role in multidisciplinary team that are responsible for treating patients
with locally advanced or metastatic GIST. This is the first conclusive message forthcoming from this book. On
the other hand, the book provides summarised and case-based knowledge on current management of
gastrointestinal and extragastrointestinal stromal tumours. We hope that this book may be considered as a
worthwhile timely addition to clinical science dissemination, medical education, further basic and clinical
research.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Keishiro Aoyagi, Kikuo Kouhuji and Kazuo Shirouzu (2012). The Significance of the Ki-67 Labeling Index, the
Expression of c-kit, p53, and bcl-2, and the Apoptotic Count on the Prognosis of Gastrointestinal Stromal
Tumor, Gastrointestinal Stromal Tumor, Prof. Raimundas Lunevicius (Ed.), ISBN: 978-953-51-0580-0, InTech,
Available from: http://www.intechopen.com/books/gastrointestinal-stromal-tumor/prognosis-factor-of-
gastrointestinal-stromal-tumor
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
